We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Mobile Real Time PCR Device Enables COVID-19 Detection in Near-Patient Setting

By LabMedica International staff writers
Posted on 01 Aug 2022
Print article
Image: Liberty16 Pro (Photo courtesy of Ubiquitome)
Image: Liberty16 Pro (Photo courtesy of Ubiquitome)

A mobile real time PCR device can expand COVID-19 testing capacity and enable pathogen detection with a multiplex assay at high speed, in addition to offering simplicity of use.

Ubiquitome Limited (Auckland, New Zealand) has unveiled its new COVID PCR testing tool named Liberty16 Pro that allows workplaces of up to 500 employees to conduct COVID-testing efficiently with a single, real time PCR device. Surveillance testing at onsite locations can give better early warning, as well as potentially being more cost effective than rapid antigen tests. Liberty16 Pro is an advanced version of Ubiquitome’s Liberty16 mobile real time PCR device which has FDA emergency use authorization for use with the Yale School of Public Health SalivaDirect SARS-CoV-2 assay for diagnostic purposes at certain designated CLIA laboratories.

The Liberty16 mobile PCR system had allowed workplaces to instigate surveillance - checking patients pre-admission, monitoring staff, splitting teams into shifts, and keeping vital supply chain services running. After training by Ubiquitome, many companies and organizations set up dedicated rooms on site and interpret sample results with ease through Ubiquitome's proprietary mobile phone app. Ubiquitome has now developed an advanced version of Liberty16 to expand testing capacity and enable pathogen detection with a multiplex assay and even greater speed - while retaining the existing simplicity of use. The Liberty16 and Liberty16 Pro are research use only devices, not for diagnostic purposes.

"The need for diagnostics that advance clinical care and public health has never been greater with the mutation of Omicron variants picking up speed," said Dr. Paul Pickering, Ubiquitome's CEO. "Developments in the Liberty16 Pro potentially expand testing capacity without sacrificing the assay's detection sensitivity, while further reducing test consumable costs and retaining the unique features which are best fit to a near-patient setting."

Related Links:
Ubiquitome Limited 

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.